Subsequent Events	3 Months Ended
Mar. 31, 2026
Subsequent Events [Abstract]
Subsequent Events	Note 11 – Subsequent Events Exercise of Pre-Funded Warrants On April 8, 2026, all 369,000 remaining Pre-Funded Warrants issued in connection with the January 6, 2026 Registered Direct Offering at an exercise price of $0.00001 per warrant share were exercised. As a result, the Company issued 369,000 shares of Common Stock to Armistice Capital Master Fund. Following this exercise, no Pre-Funded Warrants from the January 2026 offering remain outstanding. Except as described above, the Company did not identify any other subsequent events that would require recognition or disclosure in these unaudited condensed consolidated financial statements.

Subsequent Events

3 Months Ended

Mar. 31, 2026

Note 11 – Subsequent Events

Exercise of Pre-Funded Warrants

On April 8, 2026, all 369,000 remaining Pre-Funded Warrants issued in connection with the January 6, 2026 Registered Direct Offering at an exercise price of $0.00001 per warrant share were exercised. As a result, the Company issued 369,000 shares of Common Stock to Armistice Capital Master Fund. Following this exercise, no Pre-Funded Warrants from the January 2026 offering remain outstanding.

Except as described above, the Company did not identify any other subsequent events that would require recognition or disclosure in these unaudited condensed consolidated financial statements.

Estrella Immunopharma, Inc. 10-Q